Other · developed by Novartis Pharmaceuticals
PKN605 is an oral tablet studied under fasted conditions in participants with moderate and severe renal impairment and in healthy participants.
Summary written with AI from the sources listed at the end of this page.
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →